Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning Susan Corbridge, PhD, Alanna Kavanugh, MSN, CCRN

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

Thunderstorms Linked to Surge in Asthma ER Visits

Todays Updates

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Todays Updates

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life

Latest News

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

News All Time

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Guidelines in Review: CHEST Advises Against Routine Blood Transfusions for Critically Ill Patients During Procedures Kevin Kunzmann

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Recommended News For You

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

Researchers discuss HER2-low and HER2-zero in breast cancer

Radiation therapy for patients with breast cancer

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC

Recommended Articles For You

All You Need to Know About Mesna: The Ultimate Guide 

Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment 

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer 

Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo causes lasting physical decline in breast cancer survivors

2.

Virtual Reality Travel Reduces Cancer Pain.

3.

High weight and obesity are associated with poor outcomes in leukemia treatment.

4.

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

5.

Second opinions don't significantly delay breast cancer treatment

1.

Improving TIVAP Use: Review of Standardization and Optimization Practices

2.

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers

3.

Understanding Axitinib: What You Need To Know For Your Treatment Plan

4.

Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence

5.

Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

3.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot